Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)

Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the following conclusion.
Based on the criteria of the Medicines Reimbursement System (GVS), daclizumab is interchangeable with interferon beta products (interferon beta-1a, interferon beta-1b, peginterferon beta-1a) and glatiramer acetate (Copaxone ® ), which are included in the GVS.